Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE: Abatacept Safety in RA
NCT00048932Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2002
- Primary completion
- Oct 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Death, Serious Adverse Events, Related SAEs, SAEs Leading to Discontinuation, Adverse Events, Related AEs, or AEs Leading to Discontinuation, Number of Participants With AEs of Special Interest and 3 more. Started Dec 2002; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00048932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048932.